Sign up Australia
Proactive Investors - Run By Investors For Investors

Arev Nutrition Sciences set to acquire cannabis strain company BC Bud Depot in C$5.25mln deal

BCBD has one of the world's largest seed banks and has won over 40 awards over the past 14 years.
Arev Nutrition Sciences set to acquire cannabis strain company  BC Bud Depot in C$5.25mln deal
BCBD has one of the globe's largest seed banks

Arev Nutrition Sciences Inc (CSE:AREV) is set to buy cannabis strain-focused  BC Bud Depot (BCBD) in a C$5.25mln deal, which provides the company with immediate revenue in legal jurisdictions, it said.

BCBD has one of the world's largest seed banks and has won over 40 awards over the past 14 years. Its breeding methods for new cannabis strains are available for licence to licenced production companies.

AREV also noted that in 2004, it was the first Canadian company in history to win a top strain at international competition with 'BC God Bud'.It has held the inside cover of High Times Magazine for the last ten years and remains among the most recognised names in cannabis genetics and breeding.

"This acquisition brings AREV into immediate revenue in legal jurisdictions. It also completes a very important part of the company's strategy to differentiate from cultivators while bringing them a secure source of revenue," Mike Withrow, director at AREV, told investors.

"This ensures that AREV will have consistent raw materials for ingredients that are extracted from the specific genetics grown for targeted areas of health and recreational experiences.

"These extracts will be used in the company's formula's for finished products and marketed in legal jurisdictions throughout the world."

The consideration is for 9.5mln AREV shares at a deemed price of 50 cents per share and C$500,000, of which $50,000 is payable in cash and C$450,000 is payable by way of a convertible debenture issued by the company, accruing interest at 8% per year, for a total value of C$5.25mln.

BC BUD Depot added: "This partnership allows us to accelerate breeding programs designed to improve existing strains and to release new cannabis strains likely to perform well in regulated markets both within Canada and, through licensed exports of genetic material, in legal jurisdictions worldwide."

German unit

Also in today's news release, the firm said it had acquired DEUTSCHE MEDIZINAL CANNABIS UG (DMC), which will become the group's wholly owned German subsidiary.

This is a strategic purchase as the procedure for granting production and distribution licenses for medical cannabis in Germany has been halted by a court decision and no licenses have been granted to any company in Germany.

DMC is one out of only 26 companies (of 118 that participated) which had been considered eligible by the relevant ministry, at all.

The acquisition cost €18,000 paid to four vendors, AREV said.

Shares were unchanged at C$0.56.

View full AREV profile View Profile

AREV Nutrition Sciences Inc. Timeline

Related Articles

Warsaw
April 10 2018
The goal is to have 70 stores by the end of 2018 and 100 by 2020

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use